Nukkleus eyes acquisitions in air defense sector
NEW YORK - Nukkleus Inc. (NASDAQ: NUKK), a $53.37 million market cap company whose stock has surged over 1,000% in the past six months according to InvestingPro data, has announced a strategic ...
Nukkleus sees opportunities in Air Defense, partners with Translink
Nukkleus (NUKK) has partnered with Translink Corporate Finance to identify acquisition opportunities in the air defense ...
Nukkleus up 11% afterhours at $28.47 on Translink pact
EST Nukkleus (NUKK) up 11% afterhours at $28.47 on Translink pactInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to ...
Le Lézard1d
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
AN2 Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, ...
Le Lézard1d
Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone
Innocan Pharma Corporation ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its subsidiary, BI Sky Global (BI), successfully ...
Nukkleus Sees Accelerating Opportunities in Air Defense Thanks to Trump Executive Order to Develop U.S. 'Iron Dome'
Nukkleus Inc. (NASDAQ: NUKK) has partnered with Translink Corporate Finance to identify acquisition opportunities in the air defense sector, leveraging Translink's extensive expertise in mergers and ...